New Drug Combo Successful at Clearing All Hep C Genotypes | Hepatitis Central

The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Menu Search
Previous

Nutrition’s Role in Rebuilding Liver Cells After Beating Hepatitis C

Back to News Homepage
Next

New Virus Discovered: Human Hepegivirus-1 (HHpgV-1)

New Drug Combo Successful at Clearing All Hep C Genotypes

The Editors at Hepatitis Central
September 23, 2015

Print this page

Learn more about Gilead’s drug combination of velpatasvir and sofosbuvir, which is proving to be extremely effective in recent trials of clearing all strains of Hepatitis C.
Pin it on Pinterest

Gilead’s hepatitis C drug works against all strains in trial

By Doni Bloomfield

Tuesday, September 22, 2015

An experimental hepatitis C drug combination from Gilead Sciences Inc. wiped out all strains of the virus in a large clinical trial, giving the company an advantage against AbbVie Inc. in the race to treat as many patients as possible.

In a trial of 624 patients with any of six strains, or genotypes, of hepatitis C, Gilead’s experimental combination of velpatasvir and sofosbuvir was effective at clearing the virus 99 percent of the time after 12 weeks of therapy. Three related trials also showed the drug was successful in treating multiple strains, the Foster City biotech company said this week.

Continue reading this entire article:
http://www.sfgate.com/business/article/Gilead-s-hepatitis-C-drug-works-against-all-6522464.php

10 Comments
Share
Share
Previous

Nutrition’s Role in Rebuilding Liver Cells After Beating Hepatitis C

Back to News Homepage
Next

New Virus Discovered: Human Hepegivirus-1 (HHpgV-1)

Requirements for using and reposting articles

Comments

HepatitisCentral.com provides information regarding hepatitis and liver disease. Comments are available to the community in order to discuss these topics and obtain answers to questions through community members. The Editors at HepatitisCentral.com will not be responding to questions or comments posed in article comments.